NY-ESO-1

NY-ESO-1 is a human tumor antigen of the cancer/testis family.[1] It is highly expressed in many poor-prognosis melanomas.[2]

It is being studied as possible target for a cancer vaccine or immunotherapy.

It is a target for some experimental engineered T-cell therapies for myeloma.[3]

See also

References

  1. ↑ Gnjatic, S; et al. (2006). "NY-ESO-1: review of an immunogenic tumor antigen". Advances in Cancer Research. 95: 1–30. doi:10.1016/S0065-230X(06)95001-5. PMID 16860654.
  2. ↑ van Rhee, F (15 May 2005). "NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses" (PDF). Blood. 105 (10): 3939–3944. doi:10.1182/blood-2004-09-3707.
  3. ↑ Rapoport, AP; et al. (20 July 2015). "NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma". Nature Medicine. 21 (8): 914–921. doi:10.1038/nm.3910. PMC 4529359Freely accessible. PMID 26193344.

Further reading


This article is issued from Wikipedia - version of the 7/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.